| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2664 |
| Trial ID | NCT04847596 |
| Disease | Multiple Sclerosis |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | COVID-19 mRNA Vaccine |
| Co-treatment | Ofatumumab |
| Recruitment status | Completed |
| Title | An Open-label Multicenter Single-arm Pilot Study to Assess Immune Response to COVID-19 Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously |
| Year | 2021 |
| Country | United States|Puerto Rico |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | COMB157GUS18 |
| Cohort 1 | |||||||||||
|
|||||||||||